---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042322"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:28:08.950882+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virpax Q1 2024 operating loss $3.2M, cash $1.9M; Probudur study shows tolerability

## Summary
- Operating loss of $3.2M compares to $1.5M in Q1 2023, driven by higher G&A and R&D spend.
- Cash at March 31, 2024 was approximately $1.9M.
- Probudur maximum tolerated dose study: all doses well-tolerated, no noteworthy effects on body weight or clinical parameters.
- Litigation settlement with Sorrento Therapeutics approved by bankruptcy court; initial payment made March 18, 2024.
- Pilot study of Probudur in rat model showed reduction in incision-induced pain behaviors.

## SEC filing metadata
- accession: 0001213900-24-042322
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/0001213900-24-042322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/ea0205936-8k_virpax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042322
- JSON: https://secwatch.observer/filing/0001213900-24-042322.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042322.txt

## Key facts
- Earnings Releases
  Virpax Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2024.
  - Period: the three months ended March 31, 2024
  - Result: reported results
  source text: Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/0001213900-24-042322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.